Interview with Sonia Madigan – The Deal Room

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore was recently interviewed by Sonia Madigan – The Deal Room of The Market Herald, answering questions regarding the Company’s capital raise to fund a human clinical study of its gastrointestinal health product (GaRP) in irritable bowel syndrome (IBS), as well as providing an overview of the Company’s achievements and outlook.

Anatara Lifesciences (ASX:ANR) is developing and commercialising a range of gastrointestinal health products focused on animal and human health. The company’s lead product, Gastrointestinal ReProgramming (GaRP), is a microbiome-targeted complementary medicine. The product is designed to address the primary underlying factors associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

Anatara Lifesciences Limited ASX Small & Mid Cap Conference

ASX:ANR
8 September 2020

“Anatara Lifesciences Ltd (ASX:ANR) chief executive officer Steve Lydeamore speaks at the virtual ASX Small and Mid-Cap conference 2020.”

Please click on the link below for the video of the presentation:

Anatara Lifesciences with Proactive at ASX Small and Mid-Cap Conference

Proactive
8 September 2020
By mailto:andrew.scott@proactiveinvestors.com

“Anatara Lifesciences Ltd (ASX:ANR) chief executive officer Steve Lydeamore speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap conference 2020.The life sciences company is developing and commercialising innovative, evidence-based products for gastrointestinal…”

Please click on the link below for the full article:
https://www.proactiveinvestors.com.au/companies/news/928473/anatara-lifesciences-with-proactive-at-asx-small-and-mid-cap-conference-928473.html

RaaS Group Research Report

RaaS Group has released its research report on Anatara Lifesciences (ASX:ANR) ahead of the ASX Small and Mid-Cap Conference 2020.

“Going with the gut”

Please open the attached PDF to view the report.

Anatara initiates challenge study in poultry

BiotechDispatch
11 AUGUST 2020

Anatara Lifesciences (ASX:ANR) had updated on the initiation of a challenge study in poultry with recently developed bromelain-based formulation (ANR-pf).

Anatara recently said it was finalising discussions with third parties to progress challenge trials of its animal health assets to address barriers to partnering.

The company has entered into an agreement with the University of New England’s Poultry Hub Australia to undertake the study ‘Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges’.

It said the study is anticipated to be completed by 31 January 2021. The project is supported by the Poultry Hub Australia, formerly the Poultry CRC, through funding from AgriFutures Australia as part of its AgriFutures Chicken Meat Program.

Necrotic Enteritis (NE) is the most common and financially devastating bacterial disease in modern broiler flocks.

Please click on the link below for the full article:
https://biotechdispatch.com.au/news/anatara-initiates-challenge-study-in-poultry

These ASX stocks are fighting gastrointestinal disease

STOCKHEAD
5 FEBRUARY 2020
By Nick Sundich

Gastrointestinal diseases are among the most inconvenient types of illnesses to have, and not just because they may have you running to the loo every five minutes.

The field covers many diseases like Irritable Bowel Syndrome (IBS), Crohn’s Disease and colon cancer.

And the symptoms of these diseases are a punishment in themselves including internal pain, bloating and diarrhoea.

But fear not, a handful of ASX small caps are developing treatments for these diseases.

One is Anatara Lifescience (ASX:ANR) which not only targets humans but animals as well.

Antara’s human asset is a dietary supplement it calls Gastrointestinal ReProgramming (GaRP). GaRP targets gut inflammation by inhibiting pro-inflammatory proteins.

Anatara says pre-clinical evidence has shown it has a significant impact, but a clinical trial on humans will only begin next quarter.

Meanwhile, it’s animal health asset, Detach, attacks scour in piglets. The company is currently looking for a partner to licence and commercialise Detatch.

Please click on the link below for the full article:

When your guts have gone nuts, who do you call? These ASX stocks are fighting gastrointestinal disease

Stockhead “90 Seconds With” Interview

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore was recently interviewed by Stockhead, for its “90 Seconds With” interview series, providing an overview of the Company’s gastrointestinal health products, as well as the upcoming newsflow for the next 12months.

1. Can you provide our investor audience with an overview of Anatara Lifesciences?

2. What can investors expect to see from Anatara Lifesciences over the next 6-12 months?

Anatara Lifesciences (ASX:ANR) is developing and commercialising a range of gastrointestinal health products focused on animal and human health. The company’s lead product, Detach, is a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour), which affects livestock. Anatara is also developing Gastrointestinal ReProgramming (GaRP), a microbiome-targeted dietary supplement. The product is designed to address the primary underlying factors associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

Digestive Health Supplements Market Segmentation Detailed Study with Forecast to 2028

HEALTH NEWS OFFICE
19 JANUARY 2020
By rohit@transparencymarketresearch.com

The science behind digestive health has advanced stridently over the past couple decades. Gut problems and digestive diseases have no longer remained under the sole ambit of pharmaceuticals.

Global Digestive Health Supplements Market: Notable Developments
Life sciences companies in various parts of the world are striving to come out with supplements with novel action on gut health. Recently, an Australian-based life sciences company Anatara Lifesciences has come out with a health supplement that has the potential to reprogram the gut microbiome.

Please click on the link below for the full article:

Digestive Health Supplements Market Segmentation Detailed Study with Forecast to 2028

Anatara takes next step in testing its answer to US$8 billion global IBS issue

TechInvest Magazine Online
DECEMBER 20, 2019 BY STAFF WRITER

Anatara Lifesciences (ASX:ANR) has met the projected milestone to finalise a draft protocol for a human clinical trial for its GaRP dietary supplement in the treatment of irritable bowel syndrome (IBS).

CEO, Steven Lydeamore said Anatara has commenced the process of selecting a clinical research organisation (CRO) to undertake the clinical trials.

“There is a major unmet medical need and significant market opportunity for an evidence-based dietary supplement for IBS,” Mr Lydeamore said.

Click the following link for access to the full article:

Anatara takes next step in testing its answer to US$8 billion global IBS issue

Pitt Street Research Life Sciences Conference Presentation

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore presented to investors at the Pitt Street Research Life Sciences Conference in Sydney last month. Steve speaks to the Anatara story and the exciting year we have ahead with corporate milestones on both our human and animal health product opportunities.

Anatara is currently evaluating a range of evidence-based gastrointestinal consumer health products with a view to expand its current pipeline through in-licencing and distribution. In parallel, the Company continues to remain on-track to announce its human clinical trial protocol and the latest results from the second cohort as part of its current pre-clinical animal studies for its Gastrointestinal ReProgramming dietary supplement, bringing the Company closer to partnering in 2020.

The Company remains focused on building a pipeline of evidence-based human gastrointestinal health products which will provide real outcomes for patients and drive value for its shareholders.

Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

Anatara Lifesciences’ Gastrointestinal ReProgramming (GaRP) dietary supplement was recently included in Biospace’s latest Inflammatory Bowel Disease Insight Report as a preclinical candidate in the IBD drug pipeline.
Anatara Lifesciences’ lead human health product is referred to as GaRP (Gastrointestinal ReProgramming). The GaRP product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with IBD and IBS. It is being positioned as an adjunct to existing therapies and not to replace existing prescription medications. Antara has completed the preclinical program, which provided strong scientific evidence that GaRP can combat the underlying causes of chronic bowel conditions, including inflammation and dysbiosis of the microbiome.
Click the following link for access to the full article:

ABN Newswire CEO Interview

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore is interviewed by ABN Newswire, and talks about the human trials as well as the product pipeline for next year.

Anatara recently released an exciting announcement to the market having received statistically significant efficacy data from their in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product. GaRP is a proprietary dietary supplement designed to restore and maintain a healthy human gut and microbiome.

CEO interview for Morgan’s “Under the Microscope” podcast series

Under the Microscope Podcast with Scott Power

28 OCTOBER 2019 MORGANS
SCOTT POWER

Anatara Lifesciences CEO Steve Lydeamore sat down with Morgans healthcare analyst Scott Power this week for the “Under the Microscope” podcast series, speaking to Anatara’s recent proof of concept in vitro and in vivo results, the huge unmet medical need for complementary medicines in the gut health space and the Company’s next steps towards a human clinical trial and partnering in 2020.

Listen to the podcast interview here.

Morgans is Australia’s largest national full-service stockbroking and wealth management network with more than 240,000 client accounts, 500 authorised representatives and 950 employees operating from offices in all states and territories.

NUTRAingredients “Reprogramming the microbiome”

Reprogramming the microbiome: Anatara Lifesciences targets the human health space with dual targeted formulation

21 OCTOBER 2019 NUTRAingredients

Tingmin Koe

Anatara CEO, Steven Lydeamore, was recently interviewed by NUTRAingredients Editor, Tingmin Koe, about how Anatara’s Gastrointestinal ReProgramming (GaRP) dietary supplement has the ability reduce inflammation, address microbiome dysbiosis and promote mucosal healing. There is a significant unmet medical need for products that can address these factors which contribute to the primary symptoms experienced by patients suffering chronic bowel conditions such as irritable bowel syndrome and the inflammatory bowel diseases.

Click the following link for access to the article – https://www.nutraingredients.com/Article/2019/10/22/Reprogramming-the-microbiome-Anatara-Lifesciences-targets-the-human-health-space-with-dual-targeted-formulation

NutraIngredients has been the leading online news source for the nutrition industry for more than 15 years, providing a 360-degree view of the global functional food and supplement market, spanning everything from investment, incubation and innovation, to ingredients, food science and product formulation, labelling, litigation, regulation, consumer trends, new products and new technology.

Stockhead’s “The Health Kick” podcast with Tim Boreham

The Health Kick Podcast with Tim Boreham: Anatara Lifesciences

16 OCTOBER 2019 STOCKHEAD
TIM BOREHAM

Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead’s new podcast series, “The Health Kick”, speaking to how Anatara plans to stand out in the gut health market, solve scours in livestock and the future of antibiotics in the food chain.

Listen to the podcast interview here.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Stockhead is a free, journalistic news service dedicated to covering the stories of emerging, ASX-listed companies.

Australasian Biotechnology – The role of complementary medicines in managing chronic bowel conditions

In the latest edition of the Australasian Biotechnology Journal, vol29, no2, Anatara CSO, Dr Tracey Brown, talks to the role of complementary and alternative medicines in managing chronic bowel conditions such as Irritable Bowel Syndrome and Inflammatory Bowel Disease, and how Anatara hopes to demonstrate its Gastrointestinal ReProgramming (GaRP) dietary supplement has the ability to induce and maintain remission in patients suffering from chronic bowel disorders.

Click the following link for access to the complete journal edition- https://www.ausbiotech.org/documents/item/585

Dr Boreham’s Crucible “Anatara Lifesciences”

30 AUG 2019 BIOTECH DAILY
2 SEP 2019 STOCKHEAD
TIM BOREHAM

Anatara’s greater prospects lie with human health, as a remedy for the common but difficult-to-treat afflictions of irritable bowel syndrome and inflammatory bowel disease(ulcerative colitis and Crohn’s disease).

Mr Lydeamore notes that gut health is “very topical”, which is an understatement given the range of digestion-related ‘wellness’ products purveyed by the likes of Blackmores and Suisse. “If you do a Google search on the topic you will get more than 400 million hits,” he says.

He’s right: your columnist’s rigorous cross-checking of this claim reveals 530 million online references.

For the full article, please click here –
Dr Boreham’s Crucible – Anatara Lifesciences

Biotech Daily “Bioshares Gut Health & the Microbiome Session Report”

30 JUL 2019 BIOTECH DAILY
MAX LIDDLE

The companies which presented in the Gut Health and Microbiome session at the 2019 Bioshares Biotech Summit are approaching the problem of untangling the complexity of the microbiome from different directions.

Anatara Lifesciences – Seeking Clinical Validation for GaRP

Steve Lydeamore, CEO of Anatara Lifesciences, outlined their strategy of utilising a specific dietary element to target the interface of the microbiome and the body. This product, named GaRP (Gastrointestinal Reprogramming Product), acts to “remove bacteria with pro-inflammatory properties” and “stimulate mucosal healing”.

The function of this product seems to be similar to that of a prebiotic, an emerging but competitive niche in the gastro-intestinal health market.

Anatara Lifesciences’ strategy of seeking clinical validation for this product will do well to set it apart from other prebiotics which usually trade as nutritional supplements.

To read the full article, please click 190731 – Bioshares802 Summit Summary

Pitt Street Research Report

Pitt Street Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a $1.09/share base case and $3.20/share optimistic case valuation range.

“Detach upside remains”

Please open the attached PDF to view the report.

PAC Partners Research Report

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report provided a SPEC BUY rating and a price target of $0.90 per share.

“Life after Zoetis”

Please open the attached PDF to view the report.

PAC Partners Research Report

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

“World IBD Day – Sunday 19 May – ANR offers natural treatment”

Please open the attached PDF to view the report.

Finance News Network Interview with CEO

Anatara Lifesciences CEO Steve Lydeamore sat down with Anna Napoli at Finance News Network. The Finance News Network is Australia’s largest provider of online business and finance news.

Steve sat down with Anna to talk about our upcoming clinical studies and lead Gastrointestinal Reprogramming dietary supplement product candidate for Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Steve discusses the completion of our pre-clinical in vitro proof of concept studies, which demonstrated our products’ ability to address three shared characteristics of these conditions – inflammation, impaired intestinal barrier function and mucosal damage. The timeframe for partnering our dietary supplement product candidate is 18 to 24 months.

Pitt Street Research Interview with CEO

Stuart Roberts of Pitt Street Research recently sat down with Steve Lydeamore, CEO of Anatara Lifesciences (ASX: ANR) to talk about the path to market for the company’s new dietary supplement product, called GaRP (gastrointestinal reprogramming).

Based on bromelain, GaRP has shown promise as a potential treatment for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Anatara believes there is significant upside for this product given the lack of strong treatment alternatives and the high prevalence of IBS and IBD.

Morgans Interview with Anatara CEO

Anatara Lifesciences CEO Steve Lydeamore sat down with Scott Power, Senior Research Analyst at Morgans Financial Limited yesterday to talk about the Company’s plans in human gastrointestinal health; developing a unique dietarysupplement to help IBS and IBD patients in the growing gut health market.

Proactive Investors CEO Interview

Anatara Lifesciences is pleased to release a copy of Anatara CEO, Steve Lydeamore, recent interview with Ky Chow of Proactive Investors Australia about the healthcare company’s renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).

Lydeamore says the biotech firm’s dietary supplement is unlike other gut health products at the pharmacy because it seeks to repair lining of the gut.

ABN Newswire CEO Interview

Anatara Lifesciences is pleased to release a copy of Anatara CEO, Steve Lydeamore, recent interview with Tim McKinnon of ABN Newswire on the development of its Irritable Bowel Syndrome (IBS) dietary supplement to address the growing need for a product that addresses the full range of IBS symptoms.

Pitt Street Research Report

Pitt Street Research Valuation Report – “Following the gut”

Pitt Street Research has released its follow-up research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $1.34 base case and $3.61 optimistic case using a probability-weighted DCF valuation approach.

Please click on the PDF to view the report.

Stockhead “This small cap biotech proves it is possible to have more women than men on a board”

8 MARCH 2019 STOCKHEAD
Angela East

What better time than International Women’s Day to highlight that is entirely possible to have more women in leadership roles?

Today, all around the world, people are recognising and celebrating womens’ achievements and working to knock down the barriers that still exist in the ongoing fight for gender equality.

One ASX-listed small cap biotech has proven it is possible to not only have women in leadership positions, but it is quite possibly the only ASX-listed company to have had an all-female board at one point.

For the full article, please click here.

PAC Partners Research Report

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

“On track for GaRP supplement partner”

Please open the attached PDF to view the report.

Stockhead “IBS sufferers – Anatara Lifesciences reckons it has a breakthrough formula to help”

8 FEB 2019 STOCKHEAD
Sam Jacobs

Australian biotech Anatara is busy working on its next big idea in the market for digestive health products.

The company says it’s concluded a successful proof of concept study for a dietary supplement that treats gastrointestinal problems.

For the full article, please click here.

Mergermarket “Anatara Lifesciences seeks deals to bolster human health”

21 JAN 2019 MERGERMARKET
Louise Weihart in Sydney

Anatara Lifesciences [ASX:ANR], an Australian developer of treatments for gastro-intestinal conditions with unmet medical need, is actively seeking deals to bolster its gastro-intestinal pipeline as it moves its focus to human health, said new Chief Executive Officer Steven Lydeamore.

For the full article, please click here –
190121 – Mergermarket – Anatara Lifesciences seeks deals to bolster human health

PAC Partners Research Report

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

“Solid short term milestones”

Please open the attached PDF to view the report.

AGM Webcast

Biotech Dispatch “New CEO for Anatara Lifesciences”

15 NOV 2018 BIOTECH DISPATCH

Anatara Lifesciences (ASX:ANR) has announced the appointment of Steven Lydeamore as its CEO.

The company is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans.

Anatara’s Chair, Sue MacLeman, said the appointment is a key step in its development and transition to its focus on human health.

“We are very fortunate to have attracted someone of Steven’s calibre to lead Anatara at this important stage of the Company’s journey,” said Ms MacLeman. “Steve has demonstrated through his previous roles that he has the ability to successfully commercialise products on a global scale, driving growth and shareholder value.

The full article can be read here.

Gazette APVMA No.22

6 NOV 2018 Australian Pesticides and Veterinary Medicines AuthorityAPVMA Gazette

The APVMA Gazette No. 22 published details of the registration of Detach as a veterinary chemical product, which has now been granted by the APVMA.

Application no.: 108133
Product name: Detach
Active constituent/s: 670 mg/g bromelain
Applicant name: Anatara Lifesciences Ltd
Applicant ACN: 145 239 872
Summary of use: For aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets
Date of registration: 26 October 2018
Product registration no.: 83368
Label approval no.: 83368/108133

181106 APVMA Gazette No. 22, 6 November 2018

Appendix 4C Quarterly Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 September 2018.

Please click here to view the ASX announcement.

Appendix 3B

Anatara Lifesciences is pleased to release its Appendix 3B – New issue announcement, for the issue of 375,000 options issued to APRIL (Pork CRC), following APVMA approval of Detach, as per the terms of the Commercial Collaboration Agreement, as announced to the market on 29th October 2018.

Please click here to view the ASX announcement.

APVMA Approval for Detach

Anatara Lifesciences is pleased to announce that the Australian Pesticides and Veterinary Medicines Authority (APVMA) has registered Detach® with the approved label, “To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”.

Please click here for the ASX announcement.

Formation of Product Development Advisory Board

Anatara Lifesciences is pleased to announce the formation of its Product Development Advisory Board.

Please click Anatara Product Development Advisory Board for the ASX announcement.

Biotech Daily – ANATARA Appoints Product Development Advisory Board

23 OCTOBER 2018 BIOTECH DAILY

ANATARA LIFESCIENCES

Anatara says it has appointed a product development advisory board for its non-antibiotic, pineapple stem bromelain-derived gastro-intestinal health programs.

Anatara said the board would be chaired by Prof Peter Gibson and comprise Dr Rebecca Burgell, Dr Jakob Begun, Prof Barry Campbell and Prof Simon Keely and provide advice on issues relating to research priorities, strategies and product development programs.

Anatara fell two cents or five percent to 38 cents.

To read the full article, please click here: 181023 BD Biotech Daily – PDAB Appointments

Appendix 4G and Corporate Governance Statement

Anatara Lifesciences is pleased to release its Appendix 4G and Corporate Governance Statement for shareholders.

Please click here for the ASX announcement.

Anatara 2018 Annual Report

Anatara is pleased to release its 2018 Annual Report to its shareholders.

Please click here for the ASX announcement.

Notice of Meeting and Proxy Form

Anatara Lifesciences is pleased to release its Notice of Meeting and Proxy Form to shareholders in advance of its Annual General Meeting, to be held in Melbourne on Monday 12 November 2018 at 11am EDST.

Please click here for the ASX announcement.

Non Executive Director Resignation

Anatara Lifesciences advises that Mr Iain Ross has resigned as Non-Executive Director for personal reasons, effective as at 30th September 2018.

Please click here to view the ASX announcement.

Appendix 3B

Anatara Lifesciences is pleased to release its Appendix 3B – New issue announcement, for the issue of 750,000 options issued to Peloton Capital for Corporate Advisory Services, as announced to the market on 29th August 2018.

Please click here to view the ASX announcement.

Initial Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3X, advising the ASX that Jane Ryan was appointed a director as of 1 September 2018.

Please click here for the ASX announcement.

Initial Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3X, advising the ASX that Sue MacLeman was appointed a director as of 1 September 2018.

Please click here for the ASX announcement.

Final Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3Z, advising the ASX that Paul Grujic ceased to be a director as of 31 August 2018.

Please click here for the ASX announcement.

Appendix 4E Financial Report FY18

Anatara Lifesciences is pleased to release its Appendix 4E Annual Financial Report for the year ended 30 June 2018.

Please click here to view the ASX announcement.

Biotech Daily – ANATARA: SUE MACLEMAN, JANE RYAN IN; JAY HETZEL, PAUL GRUJIC GO

29 AUGUST 2018 BIOTECH DAILY

ANATARA LIFESCIENCES

Anatara says it has appointed Sue MacLeman and Dr Jane Ryan as non-executive chair and non-executive director, respectively, from September 1, 2018.

Anatara said Ms MacLeman would replace Dr Jay Hetzel who had been interim chairman since the retirement of co-founder Dr Mel Bridges earlier this year (BD: May 17, 2018). The company said that following the decision “to focus on the development of products and technologies in the human health sector … [it had] undertaken an extensive search to identify new directors with the relevant background and experience which has resulted in these appointments”.

To read the full article, please click here: 180829 BD Biotech Daily – New Board Appointments

Non Executive Chairman and Non Executive Director Appointments

Anatara Lifesciences (ASX:ANR) is pleased to announce the appointment of two human health focused directors to the Anatara Lifesciences Board of Directors, with Sue MacLeman joining as Non-Executive Chairman and Dr. Jane Ryan as Non-Executive Director from September 1, 2018.

Please click here for the ASX announcement.

Anatara’s Dr Tracey Mynott leaves to pursue humanitarian applications

Anatara Lifesciences Ltd announces the departure of Dr Tracey Mynott, Chief Scientific Officer. Tracey is a co-founder of Anatara and an inventor of Anatara’s Detach technology. Following the development and successful licensing of Detach to Zoetis, Tracey has made the decision to leave Anatara to pursue her long-standing passion to develop the technology to control infectious diarrhoea in developing countries.

Please click here for the ASX announcement.

Change in Substantial Holding

Form 604 – Notice Of Change Of Interests Of Substantial Holder was released to the ASX on 17th August 2018.

Please click here to view the ASX announcement.

Dr Boreham’s Crucible – Anatara Lifesciences

17 AUG 2018 BIOTECH DAILY
TIM BOREHAM

If there’s ever a case of the devil being in the detail, it’s the animal and human health outfit’s fall from investor grace after releasing an investor presentation on May 15 about its newly-inked animal health distribution deal with global giant Zoetis. Anatara shares lost almost 40 percent over the next two trading days, because the disclosed financial terms simply were not as tasty as investors expected. At least the company managed to forge a deal, unlike so many other biotechs.

Anatara’s interim CEO Dr Tracie Ramsdale said the company was pleased with the Zoetis deal because it was expanded to include multiple livestock, rather than just pigs.

To read the full article, please click here: 180820 – Dr Boreham’s Crucible – ANR Aug 17, 2018

New PAC Partners Research Report

PAC Partners Research has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

Restore human gut health with GaRP

Please open the attached PDF to view the report.

Latest PAC Partners Research Report

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

“Restore human gut health with GaRP”

Please open the attached PDF to view the report.

Appendix 4C Quarterly Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 June 2018.

Please click here to view the ASX announcement.

Investor Presentation and Strategy Update

Anatara is pleased to release its latest presentation and strategy update that will be delivered to institutional investors this week. 

Please click here to view the ASX announcement.

Letter to shareholders

Anatara is pleased to release a copy of a letter from Chairman, Dr Jay Hetzel, to shareholders which accompanies the investor presentation released today.
 
Please click here to view the ASX announcement.

Change of Director’s Notice

Anatara Lifesciences have issued an Appendix 3Y notifying the market of a change in Director’s interest for Mr Iain Ross.

Please click here to view the ASX announcement.

Change of Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3Y notifying the market of a change in Director’s interest for Dr Jay Hetzel.

Please click here to view the ASX announcement.

Final Director’s Interest Notice

Anatara Lifesciences have issued an Appendix 3Z, advising the ASX that Dr Mel Bridges ceased to be a director as of 17 May 2018.

Please click here for the ASX announcement.

Anatara CEO Dr Mel Bridges announces retirement

Anatara Lifesciences Ltd (ASX: ANR) announces that Executive Chairman, Dr Mel Bridges has informed the Board of his wish to retire from his role at Anatara with immediate effect and the Board has formally accepted his resignation.

Please click here for the ASX announcement.

Investor Presentation on Exclusive Global License Agreement with Zoetis

Anatara releases investor presentation containing structure and terms of its recently announced exclusive global license agreement for lead product, Detach® with Zoetis Inc., the leading global animal health company.

Please click here for the ASX announcement.

Small Caps “Anatara Lifesciences secures Zoetis catalyst for its novel Detach product”

15 MAY 2018 SMALL CAPS
GEORGE TCHETVERTAKOV

Anatara Lifesciences secures Zoetis catalyst for its novel Detach product

Biotechnology company Anatara Lifesciences (ASX: ANR) has teamed up with animal health developer Zoetis Inc. to develop, manufacture and distribute its Detach product.

The news is significant given that Zoetis has over 60 years’ experience in the sector and currently derives almost two thirds of its US$5.3 billion annual revenue from farm animal health products.

The exclusive licensing agreement will also include marketing of Detach, as a non-antibiotic approach to aid in the control of diarrhoeal disease – otherwise known as ‘scour’ – in livestock and horses.

To read the full article please click here: https://smallcaps.com.au/anatara-lifesciences-zoetis-catalyst-detach-product/

Exclusive Global License Agreement with Zoetis

Anatara Lifesciences is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach® as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.

Please click here for the ASX announcement.

Stockhead “Whiff of success for Anatara”

14 MAY 2018 STOCKHEAD
RACHEL WILLIAMSON

Whiff of success for Anatara as giant Zoetis takes diarrhoea treatment global

The world’s biggest animal health company Zoetis has decided to take an Australian horse diarrhoea treatment global.

Shareholders didn’t pooh-pooh the news, sending the stock up 19 per cent to $1.72. The shares cooled to $1.60 by 12.30pm AEST.

Zoetis — which is listed on the New York Stock Exchange at a value of $US40 billion — has signed an exclusive licence with Anatara Lifesciences (ASX:ANR) for its non-antibiotic diarrhoeal treatment for livestock and horses.

To read the full article please click here: https://stockhead.com.au/health/whiff-of-success-for-antara-as-giant-zoetis-takes-diarrhoea-treatment-global/

Trading Halt

The securities of Anatara Lifesciences have been placed in Trading Halt Session State at the request of the Company, pending a release of an announcement by the Company.

Please click here for the ASX announcement.

Appendix 4C Quarterly Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 31 March 2018.

Please click here to view the ASX announcement.

Courier-Mail “Anatara frustrated at long government delays”

25 FEB 2018 COURIER MAIL
LIAM WALSH

Brisbane-based drug developer Anatara Lifesciences has unleashed frustration at long Australian government delays in clearing its veterinary treatments.

Anatara has labelled the hold ups as “ridiculous” with the biotechnology company still awaiting a 2016 application to bring its pig diahorrea drug to market.

A copy of the full article can be read here: 180225 Courier-Mail – Anatara frustrated at long delays

Appendix 4D Half-year Report

Anatara Lifesciences is pleased to release its Appendix 4D Financial Report for the half year ended 31 December 2017.

Please click here to view the ASX announcement.

Biotech Daily “FDA okays Detach-Treated pigs ‘for human food’

5 FEB 2018 BIOTECH DAILY

ANATARA: FDA OKAYS DETACH-TREATED PIGS ‘FOR HUMAN FOOD’

Anatara says that the US Food and Drug Administration has provided “complete” letter for the technical section of its human food safety submission.

Anatara is developing its pineapple stem, bromelain-derived Detach as a non-antibiotic treatment for pig and human diarrhoea.

Please click here for the full article: 180205 BD Biotech Daily – Anatara

FDA Approves Human Food Safety section of dossier

Anatara Lifesciences has achieved a significant milestone in the United States of America after receiving a “complete” letter from the US Food and Drug Administration (FDA) for the Technical Section of its Human Food Safety (HFS) submission.

Please click here to view the ASX announcement.

Appendix 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 31 December 2017.

Please click here to view the ASX announcement.

Anatara receives $1.23m R&D Tax Refund

Anatara Lifesciences is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government’s Research and Development (R&D) Tax Incentive scheme.

Please click here to view the ASX announcement.

Appendix 3B – New Issue Announcement

Anatara Lifesciences is pleased to release its Appendix 3B – New issue announcement, for the issue of 36,000 options issued to staff under the Anatara Executive Option Plan.

Please click here to view the ASX announcement.

Courier Mail “Anatara aims to launch its much-delayed pig-poo drug next year in Australia”

19 NOV 2017 COURIER MAIL
LIAM WALSH

Anatara aims to launch its much-delayed pig-poo drug next year in Australia

ANATARA is hoping its delayed-pig diarrhoea treatment will be on the Australian market next year – and it’s even developed a new dosage gun to help boost sales.

“We’re all set to launch in Australia,” Anatara chairman Mel Bridges told investors at the Brisbane-based company’s annual general meeting last week.

The company has a submission with Australian regulators for its product and Mr Bridges said dealings with bureaucrats had gone smoothly with no red flags raised.

Anatara uses a substance derived from pineapples to help stop diarrhoea in pigs, and is marketing the substance as an alternative to antibiotics.

The full article can be read here: 171120 – Courier Mail – Anatara aims to launch its much-delayed pig-poo drug next year in Australia

Change in Substantial Holding

Form 604 – Notice Of Change Of Interests Of Substantial Holder was released to the ASX on 14th November 2017.

Please click here to view the ASX announcement.

Annual General Meeting 2017 Results

Anatara Lifesciences is pleased to announce the following results from the Annual General Meeting held on 13th November 2017.

At today’s Annual General Meeting all Resolutions put to Shareholders were passed unanimously on a show of hands.

Please click here to view the ASX announcement.

Chairman’s Address and AGM Presentation

Anatara Lifesciences is pleased to release the presentation and Chairman’s address provided to shareholders at the Annual General Meeting held today, 13th November 2017.

Please click here to view the AGM presentation.

Please click here for a copy of the Chairman’s Address.

Appendix 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 September 2017.

Please click here to view the ASX announcement.

Anatara Investor Presentation

Anatara Lifesciences is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Please click here to view the ASX announcement and presentation.

CommSec Executive Series Interviews CEO Mel Bridges

Anatara Lifesciences Chairman and CEO Mel Bridges sat down with Tom Piotrowski, for CommSec’s Executive Series this month to talk about the current negotiations with #1 global animal health company, Zoetis, regarding a commercial agreement for the worldwide development, distribution and marketing of ANR’s Detach product, in addition to the submission of the Company’s dossier to the Australian Pesticides and Veterinary Medicines Authority (APVMA), seeking regulatory approval to register Detach for commercial marketing in Australia.

Notice of General Meeting & Proxy Form

Anatara Lifesciences is pleased to release its Notice of General Meeting and Proxy Form for shareholders.

Please click here for the ASX announcement.

Dr Tracey Mynott to speak at the TRI Science Business Inspiration Series

Anatara Lifesciences CSO, Dr Tracey Mynott, will speak at the first session of the Science Business Inspiration Series next week.

SESSION 1 – THE WHOLE JOURNEY: FROM IDEA TO REALITY

For more information click here.

Appendix 4G and Corporate Governance Statement

Anatara Lifesciences is pleased to release its Appendix 4G and Corporate Governance Statement for shareholders.

Please click here for the ASX announcement.

Annual Report to Shareholders

Anatara is pleased to release its 2017 Annual Report to its shareholders.

Please click here for the ASX announcement.

Anatara Extends Pork CRC Options

Anatara Lifesciences has today undertaken to extend by 12 months the expiry date of 250,000 Options which Anatara issued to the Pork Cooperative Research Centre (CRC) in 2015.

Please click here to view the ASX announcement.

Preliminary Final Report

Anatara Lifesciences today released its Appendix 4E and financial report for the year ending 30th June 2017.

Please click here to view the ASX announcement.

Share Cafe “Anatara Investors Look To Pig Out”

25 AUG 2017 SHARECAFE
TIM BOREHAM

Porkers of the world rejoice! If Anatara’s drug rollout goes to plan, soon their short lives in the sty will be healthier and just that little bit longer.

Anatara has won the support of global animal health arm Zoetis, a Pfizer spin-off company that has exercised an option to develop Anatara’s porcine treatment Detach.

The commercial terms are yet to be negotiated, but if it pans out as expected Zoetis will assume all the ongoing costs and Anatara will pocket some fat milestone and royalty cheques.

To read the full article please click 170825 Anatara Investors Look To Pig Out – Share Cafe

Anatara and Zoetis to negotiate terms of Detach® Commercial Agreement

Anatara Lifesciences is pleased to announce that global animal health company, Zoetis Inc. (‘Zoetis’) has exercised its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach®, with terms to be agreed.

Please click here to view the ASX announcement.

PAC Partners Research Report

PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.55 per share.

“Zoetis wants global animal distribution for Detach®”

Please open the attached PDF to view the report.

Anatara Lifesciences Trading Halt

The securities of Anatara Lifesciences have been placed in Trading Halt Session State at the request of the Company, pending a release of an announcement by the Company.

Please click here to view the ASX announcement.

PAC Partners initiates analyst coverage on Anatara Lifesciences

This month PAC Partners initiated analyst coverage on Anatara Lifesciences.

PAC has initiated coverage with a Buy rating and price target of $1.36/share.

To download the full report, please click here.

Anatara 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 30 June 2017.

Please click here to view the ASX announcement.

NEW Wilsons Research & Valuation Report

NEW Wilsons Research & Valuation Report

Wilsons Equity Research has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.66 per share.

Still have our nose in this little trough

Please open the attached PDF to view the report.

Investor Update and R&D Tax Rebate

Anatara Lifesciences is pleased to provide investors with an update on recent progress.

Please click here to view the ASX announcement.

Update to Anatara 4C Quarterly Report

Anatara Lifesciences wishes to update the description of item 1.8 in the Company’s Appendix 4C for the period ending 31 March 2017, which was released to market this morning.

Please click here to view the ASX announcement and updated quarterly report.

Anatara 4C Quarterly Financial Report

Anatara Lifesciences is pleased to release its Appendix 4C Quarterly Financial Report for the quarter ended 31 March 2017.

Please click here to view the ASX announcement.

ABC Landline Story “How pineapples could protect piglets from infection”

Diarrhoea can be deadly in pig farming. Scour, as it’s called in the industry, kills tens of thousands of piglets every year. It’s traditionally been treated with antibiotics, but a Queensland scientist has developed a powerful, natural alternative from an extract found in pineapple stems

The full story on Anatara and Detach™ was featured on Landline, today (19/03/17) and can be viewed online here.